{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-050957","form_type":"8-K","ticker":"CCEL","cik":"0000862692","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2021-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.884128+00:00","generated_at":"2026-06-28T20:43:39.996457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K","bullets":["Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.","Net income $857K ($0.10 per share) vs $784K ($0.10) in Q3 2020.","Cost of sales +4%, SG&A +3% due to $167K for Cellular Therapies Institute and $131K Duke patent license expenses.","Recorded $325K decrease in fair value of contingent consideration liability for Cord:Use earn-out.","No guidance provided; company highlights transformation into cellular therapy company."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-050957","json":"https://secwatch.observer/filing/0001564590-21-050957.json","markdown":"https://secwatch.observer/filing/0001564590-21-050957.md","text":"https://secwatch.observer/filing/0001564590-21-050957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/0001564590-21-050957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/ccel-8k_20211015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:43:39.996457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}